9 Meters Biopharma, Inc. NMTR

Set alert

Price alert · NMTR

All alert types
0.07 +0.07 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
1.04M
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-0.27
Beta
1.48
Short ratio
7.78
Inst. own
16.43%
Dividend
0.00
Ex-div date
Earnings
Aug 21, 2023
50-d avg
0.7188
200-d avg
1.73
1y target
10.38

1D chart

Chart tools
Interval

Chart is warming up

The one-day price history for NMTR has not been loaded yet. Try again in a moment.

Analyst view

Consensus: buy

Buy
Price target (mean) 10.38 +14276.7% upside
Target (low)
0.75
Target (mean)
10.38
Target (high)
20.00

Recommendation trend

  • 1 month ago 6
  • 2 months ago 6

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

NMTR analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.57-1.06 – -0.41-0.80+28.8%00.0%5
Next quarter-0.40-1.06 – 0.34-0.72+44.4%00.0%5
Current year-2.18-4.20 – -1.07-3.38+35.5%2.50M0.0%5
Next year-2.53-4.50 – -1.23-2.18-16.1%00.0%4

Upgrades and downgrades

The latest rating changes

NMTR analyst upgrades and downgrades
DateFirmActionFromTo
Jun 1, 2023CitigroupMaintainedNeutralNeutral
May 18, 2023CitigroupMaintainedNeutralNeutral
Mar 20, 2023Truist SecuritiesDowngradeBuyHold
Feb 13, 2023CitigroupInitiated—Neutral
Nov 10, 2022BMO CapitalMaintained—Outperform
Sep 27, 2022OppenheimerMaintained—Outperform
Jul 1, 2022Maxim GroupDowngradeBuyHold
Jun 22, 2022Truist SecuritiesMaintained—Buy
Jun 22, 2022BMO CapitalMaintained—Outperform
Jul 8, 2021BMO CapitalInitiated—Outperform
Jun 4, 2021CitigroupInitiated—Buy
Jan 29, 2021OppenheimerInitiated—Outperform
Sep 23, 2020William BlairInitiated—Outperform
Aug 18, 2020Brookline CapitalInitiated—Buy